Loading clinical trials...

An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes | Clinical Trials | Clareo Health

COMPLETED

An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes

A Non-interventional Cross-sectional Study to Capture the Prevalence of Cardiovascular Disease in Patients With Type 2 Diabetes - an International Observation

NCT03811288•Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

The purpose of the study is to register the occurrence of cardiovascular disease among type 2 diabetes patients across ten countries across the world. Participants will be asked to give information about their health. Participants will continue their normal way of life and will not get any medication other than prescribed to them by their doctor. Participants' participation will be one day/one visit at their doctor. The study will last for about 6 months in total.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
•Male or female, age more than or equal to 18 years at the time of signing informed consent (in Algeria more than or equal to 19 years; in Japan more than or equal to 20 years).
•Diagnosed with T2DM more than or equal to 180 days prior to the day of signing the informed consent

Exclusion Criteria

•Previous participation in this study. Participation is defined as having given informed consent in this study
•Diagnosed with Type 1 diabetes
•Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
•Patients with known congenital heart disease/malformation

Locations (164)

Novo Nordisk Investigational Site

Algiers, Algeria

Novo Nordisk Investigational Site

Batna City, Algeria

Novo Nordisk Investigational Site

Constantine, Algeria

Novo Nordisk Investigational Site

Tiaret, Algeria

Novo Nordisk Investigational Site

Tizi Ouzou, Algeria

Novo Nordisk Investigational Site

Buenos Aires, Argentina

Novo Nordisk Investigational Site

Buenos Aires, Argentina

Novo Nordisk Investigational Site

Buenos Aires, Argentina

Novo Nordisk Investigational Site

Buenos Aires, Argentina

Novo Nordisk Investigational Site

CABA, Argentina

Key Dates

Start Date

December 10, 2018

Primary Completion Date

September 30, 2019

Completion Date

September 30, 2019

Last Updated

June 9, 2020

Enrollment

7,548

ACTUAL participants

Conditions

Diabetes Mellitus, Type 2

Interventions

No treatment given

OTHER

Sponsors

Lead Sponsor

Novo Nordisk A/S

Related Studies

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

NCT06959901

Obesity and Diabetes Mellitus, Type 2Diabetes Prevention

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035

Diabetes Mellitus, Type 2Depressive Symptoms+1 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 9, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions